Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Enigma and Applera sign real-time PCR licenses
These agreements provide Enigma with access under patents owned or controlled by Applera for real-time PCR thermal cyclers and real-time PCR methods and compositions in specific fields. The
These agreements provide Enigma with access under patents owned or controlled by Applera for real-time PCR thermal cyclers and real-time PCR methods and compositions in specific fields. The
Esomeprazole is a generic equivalent to Nexium which is indicated for the short-term treatment (four to eight weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive
Emisphere’s eligen technology is the basis of the company’s unique and improved delivery of therapeutic molecules and pharmaceutical compounds. Michael Novinski, president and CEO of Emisphere, said: “This
Of the shares being sold in the offering, 3.26 million shares are being issued and sold by Biodel and 550,000 shares are being sold by certain stockholders of
With the last of the 140 patients randomized in the trial having completed the dosing stage of the study, Symbollon is focused on closing the database. The company
The CryoValve SG pulmonary human heart valve is indicated for the replacement of diseased, damaged, malformed or malfunctioning native pulmonary valves. The valve can be used in conjunction
The company’s management team and board of directors subscribed for an aggregate of 1.36 million units in the offering.Each unit issued under the offering consisted of one share
Under the terms of the agreement, Royalty Pharma exercised its option to purchase a second royalty interest for $2.5 million. Royalty Pharma purchased a first royalty interest from
This ASR program falls under the previously announced authorization by Alkermes’s board of directors to repurchase up to $175 million of the company’s common stock. Prior to initiating
In support of Mr. Kailian’s appointment, four of the vompany’s largest shareholders, MPM Capital, Great Point Partners, Oxford Biosciences and Venrock, have agreed to a six-month lock-up agreement.